| dc.contributor.author | Gashlin, Lauren Z. | en_US |
| dc.contributor.author | Groth, Christine M. | en_US |
| dc.contributor.author | Wiegand, Timothy J. | en_US |
| dc.contributor.author | Ashley, Elizabeth | en_US |
| dc.date.accessioned | 1399-07-09T12:21:52Z | fa_IR |
| dc.date.accessioned | 2020-09-30T12:21:52Z | |
| dc.date.available | 1399-07-09T12:21:52Z | fa_IR |
| dc.date.available | 2020-09-30T12:21:52Z | |
| dc.date.issued | 2015-03-01 | en_US |
| dc.date.issued | 1393-12-10 | fa_IR |
| dc.date.submitted | 2014-11-17 | en_US |
| dc.date.submitted | 1393-08-26 | fa_IR |
| dc.identifier.citation | Gashlin, Lauren Z., Groth, Christine M., Wiegand, Timothy J., Ashley, Elizabeth. (2015). Comparison of Alcohol Withdrawal Outcomes in Patients Treated with Benzodiazepines Alone versus Adjunctive Phenobarbital: a Retrospective Cohort Study. Asia Pacific Journal of Medical Toxicology, 4(1), 31-36. doi: 10.22038/apjmt.2015.3984 | en_US |
| dc.identifier.issn | 2322-2611 | |
| dc.identifier.issn | 2322-4320 | |
| dc.identifier.uri | https://dx.doi.org/10.22038/apjmt.2015.3984 | |
| dc.identifier.uri | http://apjmt.mums.ac.ir/article_3984.html | |
| dc.identifier.uri | https://iranjournals.nlai.ir/handle/123456789/420573 | |
| dc.description.abstract | <em>Background:</em> For treatment of severe alcohol withdrawal syndrome, high dose benzodiazepines (BZDs) may cause delirium and over-sedation. Phenobarbital (PBT) is a long-acting barbiturate effective for the treatment of alcohol withdrawal. Given the potential benefits of PBT, we sought to investigate the effectiveness of PBT as adjunctive treatment for alcohol withdrawal. <br/><em>Methods:</em> This was a retrospective cohort study on patients with a diagnosis of alcohol withdrawal who had a CIWA-Ar score > 10 treated with either BZDs alone (BZD alone group) or BZDs with adjunctive PBT (PBT-adjunct group). The patients received at least one dose of PBT in addition to BZDs (variable doses) in the PBT-adjunct group, and three doses of 20 mg diazepam equivalents within 6 hours in the BZD alone group. The primary endpoint was the proportion of patients with a CIWA-Ar score < 10 at 24 hours after initial treatment. Duration of withdrawal and cumulative dose of BZDs were also assessed. <br/><em>Results:</em> Seven subjects in the adjunctive phenobarbital and 21 in the benzodiazepine group were included in the final analysis. Two patients (28.6%) in the PBT-adjunct group and 5 patients (23.8%) in the BZD only group achieved the primary endpoint, though the difference between the two groups was not statistically significant (P = 0.588). The median (IQR) duration of withdrawal symptoms was 44 (12-62) hours in the PBT-adjunct group compared to 53 (37-87) hours in the BZD only group, with no significant difference between the groups (P = 0.249). The median (IQR) cumulative BZD dose requirement (diazepam equivalent) in the PBT-adjunct group was significantly lower than BZD alone group (25 (20-226) vs. 326 (160-550) mg, P = 0.02). <br/><em>Conclusion:</em> PBT appears to be a safe and effective alternative to BZDs for the treatment of alcohol withdrawal in non-critically ill patients and may be BZD sparing. | en_US |
| dc.format.extent | 609 | |
| dc.format.mimetype | application/pdf | |
| dc.language | English | |
| dc.language.iso | en_US | |
| dc.publisher | Mashhad University of Medical Sciences | en_US |
| dc.relation.ispartof | Asia Pacific Journal of Medical Toxicology | en_US |
| dc.relation.isversionof | https://dx.doi.org/10.22038/apjmt.2015.3984 | |
| dc.subject | Alcohol Withdrawal Delirium | en_US |
| dc.subject | Alcoholism | en_US |
| dc.subject | Benzodiazepines | en_US |
| dc.subject | Comparative Effectiveness Research | en_US |
| dc.subject | Phenobarbital | en_US |
| dc.title | Comparison of Alcohol Withdrawal Outcomes in Patients Treated with Benzodiazepines Alone versus Adjunctive Phenobarbital: a Retrospective Cohort Study | en_US |
| dc.type | Text | en_US |
| dc.type | Original Article | en_US |
| dc.contributor.department | Department of Pharmacy, University of Rochester Medical Center, Rochester, USA | en_US |
| dc.contributor.department | Department of Pharmacy, University of Rochester Medical Center, Rochester, USA | en_US |
| dc.contributor.department | Department of Emergency Medicine, University of Rochester Medical Center, Rochester, USA | en_US |
| dc.contributor.department | Department of Pharmacy, University of Rochester Medical Center, Rochester, USA | en_US |
| dc.citation.volume | 4 | |
| dc.citation.issue | 1 | |
| dc.citation.spage | 31 | |
| dc.citation.epage | 36 | |